Weight-loss implant developer Vivani Medical's Q3 net loss widens on higher costs

By Reuters News


Overview

  • US drug-delivery implant maker's Q3 net loss widened yr/yr on higher R&D and admin costs

  • Company's cash and equivalents fell to $15.5 mln from $20.8 mln at end-Q2


Outlook

  • Cortigent-ClearOne merger expected to close shortly after final regulatory approval


Result Drivers

  • HIGHER R&D EXPENSES - Co said Q3 research and development costs rose due to increased clinical trial activity in Biopharm Division

  • HIGHER ADMINISTRATIVE COSTS - General and administrative expenses increased mainly due to higher personnel and related costs in Neurostimulation and Biopharm divisions

  • INCREASED OTHER INCOME - Other income rose due to amounts recognized under the Australian R&D Tax Incentive Program and higher interest income


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Loss Per Share

$0.08


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

  • Wall Street's median 12-month price target for Vivani Medical Inc is $4.00, about 247.8% above its November 10 closing price of $1.15


Reuters Recommended Reads

  • Nov 10 - Tyra Biosciences Q3 net loss widens on higher R&D costs

  • Nov 10 - Capricor Therapeutics Q3 net loss widens as expenses rise

  • Nov 10 - Corbus Pharmaceuticals Q3 net loss widens on higher expenses


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk